Brief: Tg Therapeutics Announces Presentation Of Data From The Ultimate I & Ii Phase 3 Trials Of Briumvi® (Ublituximab-Xiiy) In Multiple Sclerosis
25/04/2023 13:51
April 25 (Reuters) - TG Therapeutics Inc TGTX.O :
* TG THERAPEUTICS ANNOUNCES PRESENTATION OF DATA FROM THE
ULTIMATE
I & II PHASE 3 TRIALS OF BRIUMVI® (UBLITUXIMAB-XIIY) IN MULTIPLE
SCLEROSIS AT THE AMERICAN ACADEMY OF NEUROLOGY 75TH ANNUAL
MEETING
Source text for Eikon: ID:nGNXy18MC
Further company coverage: TGTX.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on TG Therapeutics
See all newsTG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj